According to filings with the U.S. Securities and Exchange Commission, Centrexion Therapeutics is raising $12,859,762.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Michael Ward played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Centrexion Therapeutics
We are passionate and committed to addressing the substantial and growing chronic pain epidemic and aim to ease the burden that moderate to severe chronic pain places on patients and our healthcare system. Our pipeline consists of novel, non-opioid therapies that are in development to potentially treat a broad array of chronic pain indications. We believe that our pipeline is uniquely positioned to address the limitations of currently-available therapies by providing safe, effective and durable pain treatment solutions. We believe that the most effective way to treat chronic pain is through therapies that specifically target the origin of the pain signal and have taken an innovative and targeted approach to identifying treatments for chronic pain that leverages our understanding of the pathophysiology of pain. We strive to maximize each of our product candidates potential based on its unique mechanism of action related to the origin of the pain signal.

To learn more about Centrexion Therapeutics, visit http://centrexion.com/

Contact:
Michael Ward, Chief Financial Officer
617-837-6911

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.